Wall Street Thinks Chemours Company (CC) Is Too Cheap To Ignore Now
BMO Capital, in a July 6 report, reiterated a Buy rating on Chemours (NYSE:CC) and set a $26 price target, near the $25 median of 11 analysts. The stock trades about 11% below the lowest target ($21). Mizuho Securities cut its target from $30 to $25 on July 1, citing lower oil prices and sector outlook changes.
How this was made
The 30-second read
Why it matters
For CC, the only actionable new information is the juxtaposition of BMO’s reiterated Buy with a $26 target and Mizuho’s lowered $25 target, both tied to broader chemical input-cost and technology-material demand narratives.
Market read
Traders may use the analyst-target spread and the oil-to-natural-gas cost thesis as context, but there is no new Chemours-specific fundamental datapoint.
What to watch
The piece does not quantify Chemours exposure to natural gas-linked feedstocks, nor does it provide segment-level demand or margin updates that would validate the sector thesis for CC.
Background
The article is a promotional-style roundup of “undervalued growth” framing, anchored to two analyst actions and a sector macro thesis.
Ticker impact
Chemours (CC) is framed as undervalued with BMO reiterating Buy and a $26 target, while Mizuho cut its target to $25.
Near-term price action likely tracks analyst-target revisions rather than new fundamentals, with limited incremental impact unless additional guidance or data emerges.
The article’s concrete updates are analyst target changes (BMO reiteration, Mizuho cut) and a sector rationale (oil price decline affecting natural gas cost advantage). No new Chemours operational metric, guidance, or event is disclosed.
Market effects
Highlights how lower oil prices can reduce natural gas cost advantages for basic chemical producers, potentially affecting sector earnings expectations.
No specific regional market linkage beyond global specialty chemicals demand.
Oil and natural gas input-cost dynamics are globally relevant for chemical margins, but the article provides no region-specific data.
Counterpoint
Analyst price targets may lag underlying fundamentals; without new Chemours-specific catalysts, the valuation argument could be crowded and slow to re-rate.
Key entities
- companyThe Chemours Company
Specialty chemicals company discussed as undervalued, with analyst target changes cited.
- analyst_firmBMO Capital
Reiterated Buy on CC with a $26 price target (July 6).
- analyst_firmMizuho Securities
Cut CC price target from $30 to $25 while keeping Outperform (July 1).
